Evidence map›Paper›PMID 42756499›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Individualized cholinergic pathway degeneration in Alzheimer's disease characterized by normative modeling.

Shuoyun Feng, Huixiang Zhuang, Chang Xu, Xinyu Guo, Li Cao, Yaou Liu, Yue Guan, Yao Li, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuoyun FengSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Huixiang ZhuangSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Chang XuSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Xinyu GuoSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Li CaoDepartment of Neurology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Yaou LiuDepartment of Radiology, Beijing Tiantan Hospital Capital Medical University Beijing China.
Yue GuanSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Yao LiSchool of Biomedical Engineering, Shanghai Sixth People's Hospital Shanghai Jiao Tong University Shanghai China.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7M
NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

introductionCholinergic pathway degeneration is implicated in Alzheimer's disease (AD), but its individualized characterization in AD and mild cognitive impairment (MCI) remains limited.

methodsWe constructed lifespan normative models of medial and lateral cholinergic pathways using >6000 diffusion MRI scans from healthy individuals. These models were applied to 1742 scans from 725 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Individualized diffusion abnormalities were integrated into a composite cholinergic pathway degeneration index (CPDI). Group differences and longitudinal associations with cognitive decline and progression were evaluated.

resultsCPDI was higher in MCI and AD participants than in controls, and increased longitudinally in patients with AD and in patients with MCI who progressed to AD. Higher baseline CPDI was associated with an increased risk of progression from MCI to AD and faster decline in global cognition, memory, language, and executive function. DISCUSSION: CPDI provides an individualized biomarker of cholinergic pathway degeneration with prognostic relevance in AD.

Indexed as

Alzheimer's diseasecholinergic pathwaydiffusion MRIdisease progressionlongitudinal studymild cognitive impairmentnormative model

Identifiers

PMID42756499
PMCPMC13583057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.